# Sleepisol

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sleepisol

- Industry: Healthcare IT
- Headquarters: Seoul, South Korea
- Website: http://leesolbrain.com
- Total disclosed funding: $5.1M
- Latest round: Series A (Feb 19, 2026)
- Investors on record: 8

## About

Founded in 2017, and based in Seoul, South Korea, LEESOL trading under the name Sleepisol operates as a healthcare IT developer that provides its clients with a platform for diagnosing and treating brain diseases. In February 2026, Sleepisol raised KRW 3 billion in series A funding led by new investor BNK Venture Capital, with participation from other new investors Spacetime Investment and Soo Investment Capital. Returning investor Vine Ventures also participated in the round. The round is part of a larger KRW 7 billion series A funding. As of 2026, the company is led by its co-CEOs Kwon Sung-sung and Lee Seung-woo.

The company will use the February 2026 funding to support advances in electronic pharmaceutical technology, new device development, global certification, and artificial intelligence-based mental health platforms.

## Funding rounds

- Series A, Feb 19, 2026, $2.1M — BNK Venture Capital, Soo Investment Capital, Vine Ventures, Spacetime Investment
- Series A, Sep 10, 2024, $3M — New Paradigm Investment, Chung-Ang University KAIC, FIND US, Vine Ventures, KOLON PHARMA

## Investors

- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Series A
- Chung-Ang University KAIC — Series A
- FIND US — Series A
- Vine Ventures — Series A
- KOLON PHARMA — Series A
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series A
- Soo Investment Capital (https://capitalatlas.ai/funds/soo-investment-capital) — Series A
- Spacetime Investment — Series A